Digital Inhaler Use in Obstructive Lung Disease Care
Feasibility, Adoption and Efficacy of Digital Inhaler in the Management of Obstructive Lung Disease
Who can join
As published by the study on ClinicalTrials.gov. "Not stated" means the study hasn't said — ask the study team.
- Age
- 18 Years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
- Compensation
- Not stated
Other requirements are listed under Eligibility below. Only the study team can confirm whether you can join.
What to expect
No one can promise a trial will help you personally — that is what the research is trying to find out.
What participation involves
Not stated in the study description — ask the study team about visits and procedures.
- Compensation
- Not stated
- Study-related exams and procedures are typically provided at no cost. This is how many trials work in general — confirm the details for this study with the study team.
- Participants are monitored closely by the research team throughout the study.
- Some participants may receive access to an investigational treatment, which is still being studied.
- Your participation helps researchers learn whether this approach could help future patients.
About this study
This is a pilot study to evaluate the role digital inhaler technology on patients with obstructive lung disease in preventing admissions and exacerbation, as well as improving symptom control. The primary objective is to evaluate feasibility of study protocol, patient recruitment, and patient retention with goal recruitment of 20 participants, 60% recruitment success, and 60% retention rate for 6 months duration. The secondary objectives are the evaluation of patient admission rate, exacerbation rates, and symptoms control with use of digital inhaler technology The subject population will be patients with physician diagnosed obstructive lung disease.
Compensation is read from the study's own description and may be missing — always confirm with the study team.
Eligibility
Official eligibility criteria
Inclusion Criteria: * Any sex * Over the age of 18 years. * Physician-diagnosed obstructive lung disease * Speak, read, and understand English. * The current study is a feasibility pilot. Based on the results of the study, future studies will include non-English speakers as well. * Able to understand study requirements and comply with study procedures. * Ability to operate a smartphone or tablet (for questionnaire and symptoms input). * Patients who use either a DPI or an MDI device as controller medications. Medications will not be changed by the study team. Exclusion Criteria: * Physically disabled such that they are incapable of using digital devices or metered dose inhalers. * Suffer from any visual, hearing or cognitive impairment that cannot be corrected enough to operate the devices properly. Mild/moderate vision loss and mild hearing loss may be included with appropriate corrective measures that do not affect the device usage. * Suffering from serious uncontrolled medical conditions that may interfere with study conduct. * Inability or unwillingness of the participant to give written informed consent. * Pregnant women (due to complicated physiology) * The current study is a feasibility pilot. Based on the results of the study, future studies will likely include pregnant patients as well. * Prisoners
Study sites (1)
CA
- Cedars-Sinai Medical Center · Los Angeles, CA 90048Vinita Kusupati · Study contact · 4016512622 · vinita.kusupati@cshs.orgVinita Kusupati, MD · Sub-investigatorSara Ghandehari, MD · Principal investigatorMore trials in Los Angeles